Examkin

Question

Difficulty: MediumInfectious Diseases

A 58-year-old man is admitted to the medical ward due to a 2-day history of severe right knee pain, swelling, and subjective fevers. He has a history of type 2 diabetes mellitus and essential hypertension. His temperature is 38.8°C (101.8°F), blood pressure is 132/82 mmHg, and pulse is 108/min. Physical examination reveals a large, erythematous, and exquisitely tender right knee effusion with significantly limited range of motion. There are no overlying skin lacerations or prior joint surgeries. Diagnostic arthrocentesis yields turbid fluid with a leukocyte count of 92,000/mm³ (94% neutrophils). Gram stain of the synovial fluid demonstrates Gram-positive cocci in clusters. The patient is promptly started on empiric intravenous vancomycin and ceftriaxone, and he undergoes urgent arthroscopic irrigation and debridement. Forty-eight hours later, he reports decreased joint pain and his temperature has normalized. Blood and synovial fluid cultures both grow Staphylococcus aureus that is resistant to penicillin but susceptible to oxacillin, cefazolin, and vancomycin. Which of the following is the most appropriate next step in targeted pharmacotherapy?

  1. Transition pharmacotherapy to intravenous cefazolinAnswer
  2. B
    Stop ceftriaxone and maintain intravenous vancomycin
  3. C
    Stop vancomycin and maintain intravenous ceftriaxone
  4. D
    Transition pharmacotherapy to oral cephalexin
  5. E
    Maintain the current antibiotics and initiate oral rifampin

Answer

The most appropriate next step is to transition the patient to intravenous cefazolin for targeted treatment of methicillin-susceptible Staphylococcus aureus (MSSA).
The patient has native joint septic arthritis and bacteremia caused by methicillin-susceptible Staphylococcus aureus (MSSA). While vancomycin is appropriately used empirically to cover potential MRSA, culture results demonstrating oxacillin susceptibility mandate de-escalation to an antistaphylococcal beta-lactam. Intravenous cefazolin (a first-generation cephalosporin) or nafcillin/oxacillin (antistaphylococcal penicillins) are the treatments of choice. They have superior bactericidal activity against MSSA compared to vancomycin, leading to faster clearance of bacteremia, lower rates of relapse, and reduced mortality. Intravenous administration must be maintained initially to ensure adequate joint penetration and to treat the concurrent bloodstream infection.

Step-by-Step Solution

1
Analyze the culture and sensitivity results
The pathogen is Staphylococcus aureus susceptible to oxacillin, making it Methicillin-Susceptible Staphylococcus aureus (MSSA).
Identifying the specific pathogen and its resistance profile is required to narrow empiric antimicrobial therapy.
2
Determine the optimal antibiotic class for the identified pathogen
Beta-lactam antibiotics (specifically antistaphylococcal penicillins or first-generation cephalosporins) are the drugs of choice for MSSA.
For MSSA, vancomycin is clinically inferior to beta-lactams, demonstrating slower clearance of bacteremia and higher mortality rates.
3
Select the appropriate route and duration of therapy
Intravenous therapy is required for deep-seated infections like septic arthritis and concurrent bacteremia.
Early transition to oral therapy is inappropriate for native joint septic arthritis at 48 hours; high serum and tissue concentrations provided by IV delivery are needed initially.

Key Concept

Definitive targeted therapy for methicillin-susceptible Staphylococcus aureus (MSSA) infections requires transitioning from empiric vancomycin to a narrower-spectrum, highly active beta-lactam such as intravenous cefazolin or nafcillin.
Estimated Time:1m 15s
Rate this question

Topics

Infectious Diseases

More questions from this topic